PhRMA Statement on Clinical Trials and Bad Pharma

Phrma: February 4, 2013

WASHINGTON, D.C. (February 4, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President Josie Martin issued the following statement today:

“Dr. Ben Goldacre’s book Bad Pharma provides a one-sided and factually questionable view of the clinical trial process led by the innovative biopharmaceutical sector. The book ignores that the current clinical trial system, which is essential to the development of new medicines that save and improve lives, is scientifically rigorous, tightly regulated and working well.

“The book’s unfounded and sensational claims may attract attention, but they do not advance biomedical science or patient health. Based on cherry-picked examples and incomplete stories, the accusations leave countless unanswered questions that could threaten public health and the development of future medicines. Criticizing the research process without acknowledging the vigorous oversight and broad commitment to safe and ethical conduct is a disservice to the tens of thousands of scientists exploring new medicines and the millions of patients hoping for cures. Read more